Want to see ABVC full AI Analyst Report?
ABVC BioPharma (ABVC) Stock Statistics & Valuation Metrics
Total Valuation
ABVC BioPharma has a market cap or net worth of $26.16M. The enterprise value is $57.74M.
- Market Cap
- $26.16M
- Enterprise Value
- $57.74M
Share Statistics
ABVC BioPharma has 26,694,475 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 26,694,475
- Owned by Insiders
- ―
- Owned by Institutions
- 4.41%
Financial Efficiency
ABVC BioPharma’s return on equity (ROE) is -0.71 and return on invested capital (ROIC) is -42.64%.
- Return on Equity (ROE)
- -0.71
- Return on Assets (ROA)
- -0.38
- Return on Invested Capital (ROIC)
- -42.64%
- Return on Capital Employed (ROCE)
- -0.48
- Revenue Per Employee
- 0
- Profits Per Employee
- -439.36K
- Employee Count
- 18
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of ABVC BioPharma is -3.34. ABVC BioPharma’s PEG ratio is 0.05.
- PE Ratio
- -3.34
- PS Ratio
- -33.04
- PB Ratio
- 2.50
- Price to FCF
- -10.75
- Price to Operating Cash Flow
- -9.54
- PEG Ratio
- 0.05
Income Statement
In the last 12 months, ABVC BioPharma had revenue of 0 and earned -7.91M in profits. Earnings per share was -0.39.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -7.15M
- Pretax Income
- -8.35M
- Net Income
- -7.91M
- EBITDA
- -7.43M
- Earnings Per Share (EPS)
- -0.39
Cash Flow
In the last 12 months, operating cash flow was -2.69M and capital expenditures 244,413, giving a free cash flow of -2.45M billion.
- Operating Cash Flow
- -2.69M
- Free Cash Flow
- -2.45M
- Free Cash Flow per Share
- -0.09
Dividends & Yields
ABVC BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.16%
- Earnings Yield
- -30.33%
Stock Price Statistics
- Beta
- 1.84
- 52-Week Price Change
- -66.72%
- 50-Day Moving Average
- 0.99
- 200-Day Moving Average
- 1.24
- Relative Strength Index (RSI)
- 46.02
- Average Volume (3m)
- 97.84K
Important Dates
ABVC BioPharma upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Mar 27, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
ABVC BioPharma as a current ratio of 0.41, with Debt / Equity ratio of 31.25%
- Current Ratio
- 0.41
- Quick Ratio
- 0.41
- Debt to Market Cap
- 0.07
- Net Debt to EBITDA
- -0.38
- Interest Coverage Ratio
- -17.20
Taxes
In the past 12 months, ABVC BioPharma has paid 24.15K in taxes.
- Income Tax
- 24.15K
- Effective Tax Rate
- -0.00
Enterprise Valuation
ABVC BioPharma EV to EBITDA ratio is -3.67, with an EV/FCF ratio of -11.62.
- EV to Sales
- -35.71
- EV to EBITDA
- -3.67
- EV to Free Cash Flow
- -11.62
- EV to Operating Cash Flow
- -10.56
Balance Sheet
ABVC BioPharma has $94.36K in cash and marketable securities with $1.76M in debt, giving a net cash position of -$1.67M billion.
- Cash & Marketable Securities
- $94.36K
- Total Debt
- $1.76M
- Net Cash
- -$1.67M
- Net Cash Per Share
- -$0.06
- Tangible Book Value Per Share
- $0.47
Margins
Gross margin is 100.00%, with operating margin of 918.55%, and net profit margin of 992.85%.
- Gross Margin
- 100.00%
- Operating Margin
- 918.55%
- Pretax Margin
- 1054.81%
- Net Profit Margin
- 992.85%
- EBITDA Margin
- 973.54%
- EBIT Margin
- 1035.31%
Analyst Forecast
The average price target for ABVC BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- -55.90%
Scores
- Smart Score
- ―
- AI Score
- 41
